Market Overview

Deutsche Bank Reiterates Buy on Sarepta Therapeutics Following Two Key Controversies

Structural Volatility Won't End For Several Years, Derivatives Strategist Says
Forbes: There Is 'A Bit' Of Hope For Sarepta Therapeutics
Recent Setbacks Have Duchenne Investors On Edge (Seeking Alpha)

In a report published Wednesday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating and $45.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).

In the report, Deutsche Bank noted, “Our base case scenario assumes Breakthrough designation for Eteplirsen. However we note that, if granted, such a designation might be at risk later on when Drisapersen comes to markets. Drisapersen will potentially reach markets in late 2014/early 2015. However, we do not know how strict will FDA be in implementing these withdrawal guidelines. We note that similar withdrawal guidelines exist for Fast Track development program but such withdrawals are uncommon. We also note that Sarepta drug has substantial safety advantage over Drisapersen which could help it retain the designation. We expect to get clarity around breakthrough designation before the start of Eteplirsen phase III trial.”

Sarepta Therapeutics closed on Tuesday at $39.73.

Latest Ratings for SRPT

Jan 2016RBC CapitalDowngradesOutperformSector Perform
Jan 2016Piper JaffrayDowngradesOverweightNeutral
Nov 2015Leerink SwannMaintainsMarket Perform

View More Analyst Ratings for SRPT
View the Latest Analyst Ratings

Posted-In: Deutsche Bank Robyn KarnauskasAnalyst Color Reiteration Analyst Ratings


Related Articles (SRPT)

View Comments and Join the Discussion!

Get Benzinga's Newsletters